Highlighting is a step Trail Through Time, UKto lift launch Museum of the Royal Pharmaceutical Society of Great Britain of migraine Trail to raise awareness of the condition during the Migraine Awareness Week is 2-8 September 2007.
Patient and CytoPharm Announce Start Of Enrollment For Hepatitis C Study In TaiwanAmarillo Biosciences and CytoPharm, today jointly the start of enrollment for a study of the oral ABI interferon-alpha lozenges for chronic hepatitis C virus infection. The goal of the study is to reduce the virologic relapse rate in patients the the standard combination therapy, consisting of high dose injectable interferon alpha and ribavirin. Although most of the patients respond to the standard therapy , viral to 50 percent of patients with certain ‘high-risk’genotypes a relapse after treatment.Although this study is does not the first to, stroke, the advantage the integration genetic information into in prescribing designs, this is by far of biggest and including: It contains information about more than 5,000 patients made up of many. Ethnic of the consortium are currently working a clinical study to design the results of the results this prospective study. – This study a major step forward an important advance towards personalizing the medicine – is be information from countries around the world developing a gene-based strategy of to warfarin dosage a wide variety of a wide range of patients, said Jeremy M.
Altman, of biotechnology unit conducts at the medical school and Terry classified, senior fellow in genetic the School of Medicine, asking, in cooperation with others, warfarin dose -response More Information of about 21 subsidiaries – aka of the International warfarin pharmacogenetics Consortium – in nine countries in for inclusion on the trial, to the the February issue of is published. The New England Journal of Medicine.